LRRK2 and neuroblastoma: A proteomics study performed in neuroblastoma cells, either expressing LRRK2 and pharmacologically treated with an enzyme inhibitor or expressing the G2019S LRRK2 mutant, led to identifying 776 phosphorylation sites whose levels changed by +/- 50% upon inhibition of the enzyme.